Volume 2015 Supplement 1
Bisphosphonates as treatment of secondary osteoporosis in children: a case series
© Soesanti et al; licensee BioMed Central Ltd. 2015
Published: 28 April 2015
Keywordssecondary osteoporosis bone mineral density bisphosphonates
Secondary osteoporosis due to chronic disease is a major pediatric health concern and has certain unique diagnostic with various clinical challenges. Bisphosphonates has been used in small numbers of pediatric patients to treat secondary osteoporosis resulted in significantly fewer fractures and improved mobility.
To present case series of secondary osteoporosis due to chronic disease treated with biphosphonate.
We included 6 patients (2 boys, 4 girls), 7–15 years of age with secondary osteoporosis who were treated with biphosphonate. Two patients were diagnosed acute lymphoblastic leukemia, two patients with systemic lupus erythematosus and others with juvenile rheumatoid arthritis. Two patients received methotrexate and dexamethasone; one patient was treated with methotrexate and prednisone; two patients with methylprednisolone; and rest with only methotrexate. Four of them suffered back pain due to trauma and from radiographic examination showed multiple compression fracture on the vertebrae. Lumbal BMD Z-score was ranging from -2.8 to -5.1 in patients who had fracture, while in patients without fracture -2.6 to -3.1. We used zoledronic acid 0.05 mg/kgBW. Two patients already received pamidronate as previous treatment. In 6 - 12 months of follow-up, there were evidence of reduced pain, improved mobility and BMD Z-score, also no evidence of new fractures in radiographic evaluation.
Bisphosphonates appears to be safe and effective as treatment for children with secondary osteoporosis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.